Aya Mohamed, Breast CA Specialist and Researcher, shared on X:
“FDA approved tucatinib + trastuzumab + pertuzumab as maintenance therapy for HER2-positive unresectable locally advanced or metastatic breast cancer after THP induction.
HER2CLIMB-05: PFS 24.9 vs 16.3 months; HR 0.64, P<0.0001.
The key question is where this strategy fits as HER2-directed therapies move earlier. OS remains immature. Longer follow-up and sequencing data will define its role.”
This also can be interesting:
Datopotamab Deruxtecan Approved in China for Advanced Triple-Negative Breast Cancer
